Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $78.86 Consensus PT from Analysts

by · The Cerbat Gem

Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $78.8571.

A number of research firms have recently issued reports on ESTA. Mizuho raised their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Canaccord Genuity Group lifted their price objective on shares of Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. upped their price objective on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Finally, Citigroup increased their price objective on shares of Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th.

Read Our Latest Research Report on ESTA

Institutional Investors Weigh In On Establishment Labs

Several hedge funds have recently bought and sold shares of ESTA. Quarry LP acquired a new position in shares of Establishment Labs in the third quarter valued at approximately $34,000. State of Wyoming acquired a new stake in Establishment Labs during the 3rd quarter worth approximately $71,000. Osaic Holdings Inc. boosted its stake in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the period. CWM LLC grew its holdings in Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after buying an additional 686 shares in the last quarter. Finally, PharVision Advisers LLC acquired a new position in Establishment Labs in the 3rd quarter valued at $203,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Stock Performance

Shares of ESTA opened at $67.51 on Wednesday. The company has a market cap of $1.96 billion, a PE ratio of -23.77 and a beta of 0.92. The firm has a 50-day moving average of $69.83 and a 200-day moving average of $52.28. Establishment Labs has a one year low of $26.56 and a one year high of $78.24. The company has a debt-to-equity ratio of 15.06, a current ratio of 3.33 and a quick ratio of 2.10.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.16. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The business had revenue of $53.78 million during the quarter, compared to the consensus estimate of $52.28 million. During the same period last year, the business posted ($0.59) EPS. Establishment Labs’s revenue was up 33.8% on a year-over-year basis. As a group, equities analysts forecast that Establishment Labs will post -2.41 earnings per share for the current year.

Establishment Labs Company Profile

(Get Free Report)

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

See Also